title: Effects of aliskiren-based therapy on ambulatory blood pressure profile, central hemodynamics, and arterial stiffness in nondiabetic mild to moderate hypertensive patients.
abstract: Aliskiren is a direct renin inhibitor that exerts its effect at the rate-limiting step of the renin-angiotensin system. This study was performed to examine the beneficial effects of aliskiren-based antihypertensive therapy on the ambulatory blood pressure (BP) profile, central hemodybamics, and arterial stiffness in untreated Japanese patients with mild to moderate hypertension. Twenty-one Japanese nondiabetic patients with untreated mild to moderate essential hypertension were initially given aliskiren once daily at 150 mg, and the dose was titrated up to 300 mg as needed. After 12 weeks of aliskiren-based therapy, the clinic, ambulatory, and central BP values as well as brachial-ankle pulse wave velocity (baPWV) were all significantly decreased compared with baseline (clinic systolic BP, 151 ± 11 mm Hg vs 132 ± 11 mm Hg; clinic diastolic BP, 91 ± 13 mm Hg vs 82 ± 9 mm Hg; 24-hour systolic BP, 144 ± 12 mm Hg vs 133 ± 11 mm Hg; 24-hour diastolic BP, 88 ± 8 mm Hg vs 81 ± 9 mm Hg; central BP, 162 ± 16 mm Hg vs 148 ± 14 mm Hg; baPWV, 1625 ± 245 cm/s vs 1495 ± 199 cm/s; P<.05). These results show that aliskiren, as a first-line regimen, improves the ambulatory BP profile and may have protective vascular effects in Japanese nondiabetic patients with untreated mild to moderate essential hypertension.
authors.affiliation: Department of Medical Science and Cardiorenal Medicinethe, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Kanaoka
authors.forename: Kouichi
authors.initials: K
authors.lastname: Tamura
authors.forename: Masato
authors.initials: M
authors.lastname: Ohsawa
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Wakui
authors.forename: Akinobu
authors.initials: A
authors.lastname: Maeda
authors.forename: Toru
authors.initials: T
authors.lastname: Dejima
authors.forename: Kengo
authors.initials: K
authors.lastname: Azushima
authors.forename: Sona
authors.initials: S
authors.lastname: Haku
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mitsuhashi
authors.forename: Mai
authors.initials: M
authors.lastname: Yanagi
authors.forename: Jin
authors.initials: J
authors.lastname: Oshikawa
authors.forename: Kazushi
authors.initials: K
authors.lastname: Uneda
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Aoki
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Fujikawa
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Toya
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Uchino
authors.forename: Satoshi
authors.initials: S
authors.lastname: Umemura
mesh_terms: D000368:Aged; D000577:Amides / Q000494:pharmacology* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D018660:Blood Pressure Monitoring, Ambulatory; D004305:Dose-Response Relationship, Drug; D005260:Female; D005650:Fumarates / Q000494:pharmacology* / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000208:ethnology / Q000503:physiopathology*; D007564:Japan; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D059289:Vascular Stiffness / Q000187:drug effects* / Q000502:physiology
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D005650:Fumarates; C446481:aliskiren